Apathy and Functional Status in Early-Stage Huntington’s Disease
These results underscore the need to address apathy as a target for improving functional status, social satisfaction, and well-being in HD, even for individuals with early-stage HD.
Authors
- Katherine E. McDonell (ORCID: https://orcid.org/0000-0003-4620-3850)
- Jessica Jiang (ORCID: https://orcid.org/0000-0002-7074-3032)
- Kaitlyn R. Hay (ORCID: https://orcid.org/0000-0003-2143-3932)
- Jessie S. Gibson (ORCID: https://orcid.org/0000-0003-4556-8428)
- David A. Isaacs (ORCID: https://orcid.org/0000-0002-9860-1052)
- Amy Wynn
- Daniel O. Claassen (ORCID: https://orcid.org/0000-0002-9853-4902)
- Amy E. Brown (ORCID: https://orcid.org/0000-0001-5752-9835)
Institutions
- University of Virginia (US)
Publication Details
- Journal
- Journal of Neuropsychiatry
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1176/appi.neuropsych.20230225
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Biogen
- CHDI Foundation
- Teva Pharmaceutical Industries
- F. Hoffmann-La Roche
- Jazz Pharmaceuticals
- PTC Therapeutics
- Neurocrine Biosciences
- Sage Therapeutics
- H. Lundbeck A/S
- National Institutes of Health
- Genentech
- National Institute on Aging
- National Institute of Nursing Research
- National Institute of Neurological Disorders and Stroke
- National Center for Complementary and Integrative Health